Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07535645) titled 'Baricitinib for Post-HSCT Persistent Thrombocytopenia' on April 6.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Peking University People's Hospital
Condition:
Persistent Thrombocytopenia
Allogeneic Hematopoietic Stem Cell Transplantation
Intervention:
Drug: Baricitinib
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: April 15, 2026
Target Sample Size: 28
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study...